Mesorectal Excision (ME) Versus ME With Lateral Node Dissection for Stage II, III Lower Rectal Cancer (JCOG0212)
NCT ID: NCT00190541
Last Updated: 2016-09-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
700 participants
INTERVENTIONAL
2003-06-30
2015-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety of Mid and Low Rectal Cancer Surgery Without Dissection of the No.253 Lymph Node (S-M-O-O-T-H)
NCT06146946
Open or Laparoscopic Mesolectal Excision in Low Rectum Cancer
NCT04561830
Trans-anal Versus Laparoscopic TME for Mid and Low Rectal Cancer
NCT03242187
Simultaneous Versus Staged Resection for Initially Resectable Synchronous Rectal Cancer Liver-limited Metastasis
NCT00677586
Low or High Ligation of the IMA With Apical Lymph Node Dissection in Rectal Cancer Laparoscopic Surgery
NCT03013153
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Procedure/Surgery: Mesorectal excision with lateral lymph node dissection
Mesorectal excision with lateral lymph node dissection
Mesorectal excision with lateral lymph node dissection
2
Procedure/Surgery: Mesorectal excision without lateral lymph node excision
Mesorectal excision without lateral lymph node excision
Mesorectal excision without lateral lymph node excision
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mesorectal excision with lateral lymph node dissection
Mesorectal excision with lateral lymph node dissection
Mesorectal excision without lateral lymph node excision
Mesorectal excision without lateral lymph node excision
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Histologically confirmed adenocarcinoma
2. Clinical stage II or III
3. Preoperative findings:
* Main lesion of the tumor is located at the rectum
* Lower tumor margin is below the peritoneal reflection
* No extramesorectal lymph node swelling (Shorter diameter is less than 10 mm)
* No invasion to other organ (s)
4. Patient age is more than 20 and less than 75
5. PS: 0, 1
6. No past history of chemotherapy, pelvic surgery or radiation
7. Written informed consent
Operative criteria:
8. Mesorectal excision is performed
9. Operative findings:
* Main lesion of the tumor is located at the rectum
* Lower tumor margin is below the peritoneal reflection
10. R0 after resection
Exclusion Criteria
2. Pregnant patients
3. Psychological disorder
4. Steroid administration
5. Cardiac infarction within six months
6. Severe pulmonary emphysema and pulmonary fibrosis
7. Doctor's decision for exclusion
21 Years
74 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ministry of Health, Labour and Welfare, Japan
OTHER_GOV
Haruhiko Fukuda
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Haruhiko Fukuda
JCOG Data Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shin Fujita, MD
Role: STUDY_CHAIR
National Cancer Center Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aichi Cancer Center Hospital
Nagoya,Chikusa-ku,Kanokoden,1-1, Aichi-ken, Japan
Fujita Health University
Toyoake,Kutsukake-cho,Dengakugakubo,1-98, Aichi-ken, Japan
Chiba Cancer Center Hospital
Chiba,Chuo-ku,Nitona-cho,666-2, Chiba, Japan
National Cancer Center Hospital East
Kashiwa,Kashiwanoha,6-5-1, Chiba, Japan
Toho University Sakura Hospital
Sakura,Shimoshidu,564-1, Chiba, Japan
Jyuntendo Urayasu Hospital
Urayasu,Tomioka,2-1-1, Chiba, Japan
National Hospital Organization Shikoku Cancer Center
Matsuyama,Horinouchi,13, Ehime, Japan
National Kyushu Cancer Center
Fukuoka,Minami-ku,Notame,3-1-1, Fukuoka, Japan
Kurume University School of Medicine
Kurume,Asahi-machi,67, Fukuoka, Japan
Kurume University Medical Center
Kurume,Kokubumachi,155-1, Fukuoka, Japan
Gunma Prefectural Cancer Center
Ota,Takabayashi-nishi-cho,617-1, Gunma, Japan
Hiroshima University, School of Medicine
Hiroshima,Minami-ku,Kasumi,1-2-3, Hiroshima, Japan
Hiroshima City Hospital
Hiroshima,Naka-ku,Motomachi,7-33, Hiroshima, Japan
Sapporo-Kosei General Hospital
North-3,East8-5,Chuou-ku,Sapporo, Hokkaido, Japan
Kansai Rosai Hospital
Amagasaki,Inabasou,3-1-69, Hyōgo, Japan
Ibaraki Kenritsu Chuo Hospital & Cancer Center
Nishi-ibarakigun,Tomobemachi,Koibuchi,6528, Ibaraki, Japan
Ishikawa Prefectual Central Hospital
Kanazawa,Kuratsuki-Higashi,2-1, Ishikawa-ken, Japan
Teikyo University Hospital, Mizonokuchi
Kawasaki,Takatsu-ku,Mizonokuchi,3-8-3, Kanagawa, Japan
Kitasato University East Hospital
Sagamihara,Asamizodai,2-1-1, Kanagawa, Japan
Kitasato University School of Medichine
Sagamihara,Kitasato,1-15-1, Kanagawa, Japan
Kanagawa Cancer Center
Yokohama,Asahi-ku,Nakao,1-1-2, Kanagawa, Japan
Yokohama City University Medical Center
Yokohama,Minami-ku,Urafunecho,4-57, Kanagawa, Japan
Showa University Northern Yokohama Hospital
Yokohama,Tsuzuki-ku,Chigasakichuo,35-1, Kanagawa, Japan
National Hospital Organization Kyoto Medical Center
Kyoto,Fushimi-ku,Fukakusa,Mukaihata-cho,1-1, Kyoto, Japan
Miyagi Cancer Center
Natori,Medeshima-Shiode,Nodayama,47-1, Miyagi, Japan
Nagano Municipal Hospital
Nagano,Tomitake,1333-1, Nagano, Japan
Niigata Cancer Center Hospital
Niigata,Kawagishi-cho,2-15-3, Niigata, Japan
Oita University Fuculty of Medicine
Oita,Hasama-machi,Oogaoka,1-1, Oita Prefecture, Japan
Okayama Saiseikai General Hospital
Okayama,Ifukucho,1-17-18, Okayama-ken, Japan
Minoh City Hospital
Minoh,Kayano,5-7-1, Osaka, Japan
Osaka National Hospital
Osaka,Chuo-ku,Hoenzaka,2-1-14, Osaka, Japan
Osaka Medical Center for Cancer and Cardiovascular Diseases
Osaka,Higashinari-ku,Nakamichi,1-3-3, Osaka, Japan
Osaka City General Hospital
Osaka,Miyakojima-ku,Miyakojimahondori,2-13-22, Osaka, Japan
Sakai Municipal Hospital
Sakai,Minamiyasuicho,1-1-1, Osaka, Japan
Osaka University Graduate School of Medicine
Suita,Yamada-oka,2-2, Osaka, Japan
Osaka Medical College
Takatsuki,Daigakucho,2-7, Osaka, Japan
Omiya Medical Center, Jichi Medical School
Saitama,Omiya-ku,Amanuma-cho,1-847, Saitama, Japan
National Defense Medical College
Tokorozawa,Namiki,3-2, Saitama, Japan
Sizuoka Cancer Center
Sunto-gun,Nagaizumi-cho,Shimonagakubo,1007, Shizuoka, Japan
Tochigi Cancer Center
Utsunomiya,Yohnan,4-9-13, Tochigi, Japan
Tokyo Medical and Dental University Hospital
Bunkyo-ku,Yushima,1-5-45, Tokyo, Japan
National Cancer Center Hospital
Chuo-ku,Tsukiji, 5-1-1, Tokyo, Japan
Toho University Ohashi Hospital
Meguro-ku,Ohashi,2-17-6, Tokyo, Japan
Toranomon Hospital
Minato-ku,Toranomon,2-2-2, Tokyo, Japan
Kyorin University School of Medicine
Mitaka,Shinkawa,6-20-2, Tokyo, Japan
Tokyo Medical University
Shinjuku-ku,Nishi-shinjuku,6-7-1, Tokyo, Japan
Keio University Hospital
Shinjuku-ku,Shinanomachi,35, Tokyo, Japan
Yamagata Prefectural Central Hospital
Yamagata,Aoyagi,1800, Yamagata, Japan
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Tsukamoto S, Fujita S, Ota M, Mizusawa J, Shida D, Kanemitsu Y, Ito M, Shiomi A, Komori K, Ohue M, Akazai Y, Shiozawa M, Yamaguchi T, Bando H, Tsuchida A, Okamura S, Akagi Y, Takiguchi N, Saida Y, Akasu T, Moriya Y; Colorectal Cancer Study Group of Japan Clinical Oncology Group. Long-term follow-up of the randomized trial of mesorectal excision with or without lateral lymph node dissection in rectal cancer (JCOG0212). Br J Surg. 2020 Apr;107(5):586-594. doi: 10.1002/bjs.11513. Epub 2020 Mar 12.
Saito S, Fujita S, Mizusawa J, Kanemitsu Y, Saito N, Kinugasa Y, Akazai Y, Ota M, Ohue M, Komori K, Shiozawa M, Yamaguchi T, Akasu T, Moriya Y; Colorectal Cancer Study Group of Japan Clinical Oncology Group. Male sexual dysfunction after rectal cancer surgery: Results of a randomized trial comparing mesorectal excision with and without lateral lymph node dissection for patients with lower rectal cancer: Japan Clinical Oncology Group Study JCOG0212. Eur J Surg Oncol. 2016 Dec;42(12):1851-1858. doi: 10.1016/j.ejso.2016.07.010. Epub 2016 Jul 30.
Fujita S, Akasu T, Mizusawa J, Saito N, Kinugasa Y, Kanemitsu Y, Ohue M, Fujii S, Shiozawa M, Yamaguchi T, Moriya Y; Colorectal Cancer Study Group of Japan Clinical Oncology Group. Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): results from a multicentre, randomised controlled, non-inferiority trial. Lancet Oncol. 2012 Jun;13(6):616-21. doi: 10.1016/S1470-2045(12)70158-4. Epub 2012 May 15.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C000000034
Identifier Type: REGISTRY
Identifier Source: secondary_id
JCOG0212
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.